[ Enlarge table ] |
| [ XLS ] |
|
|
Investments in |
Securities |
Loans |
|
| ||
|
€ million |
available |
other |
available |
financial |
and other |
Total |
Equity |
|
Acquisition cost January 1, 2006 |
28.8 |
17.6 |
5.9 |
10.5 |
29.5 |
92.3 |
1.9 |
|
Currency translation |
– |
– |
– |
– |
–0.2 |
–0.2 |
–0.3 |
|
Changes in companies consolidated |
– |
–75.7 |
– |
– |
– |
–75.7 |
– |
|
Additions |
1,578.7 |
82.5 |
– |
3.2 |
4.1 |
1,668.5 |
0.1 |
|
Disposals |
–1.3 |
– |
–0.1 |
–13.3 |
–2.8 |
–17.5 |
– |
|
December 31, 2006 |
1,606.2 |
24.4 |
5.8 |
0.4 |
30.6 |
1,667.4 |
1.7 |
|
|
|
|
|
|
|
|
|
|
Accumulated depreciation and |
|
|
|
|
|
|
|
|
impairment losses January 1, 2006 |
–17.9 |
–0.1 |
–4.3 |
– |
–0.4 |
–22.7 |
–0.4 |
|
Currency translation |
– |
– |
– |
– |
– |
– |
– |
|
Changes in companies consolidated |
– |
– |
– |
– |
– |
– |
– |
|
Depreciation and impairment losses |
–1.5 |
– |
– |
– |
– |
–1.5 |
– |
|
Disposals |
0.6 |
– |
0.1 |
– |
– |
0.7 |
– |
|
Fair value adjustments of long-term investments taken directly to equity |
–3.5 |
– |
– |
– |
– |
–3.5 |
– |
|
December 31, 2006 |
–22.3 |
–0.1 |
–4.2 |
– |
–0.4 |
–27.0 |
–0.4 |
|
|
|
|
|
|
|
|
|
|
Net carrying amount |
1,583.9 |
24.3 |
1.6 |
0.4 |
30.2 |
1,640.4 |
1.3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition cost January 1, 2007 |
1,606.2 |
24.4 |
5.8 |
0.4 |
30.6 |
1,667.4 |
1.7 |
|
Currency translation |
– |
– |
– |
– |
– |
– |
– |
|
Changes in companies consolidated |
165.6 |
–9,974.7 |
167.5 |
– |
–0.1 |
–9,641.7 |
0.3 |
|
Additions |
16.6 |
9,272.4 |
– |
11.3 |
5.8 |
9,306.1 |
0.3 |
|
Disposals |
–118.3 |
–870.2 |
–167.7 |
– |
–20.1 |
–1,176.3 |
–0.4 |
|
Transfers |
–1,575.4 |
1,575.5 |
– |
– |
– |
0.1 |
–0.1 |
|
December 31, 2007 |
94.7 |
27.4 |
5.6 |
11.7 |
16.2 |
155.6 |
1.8 |
|
|
|
|
|
|
|
|
|
|
Accumulated depreciation and |
|
|
|
|
|
|
|
|
impairment losses January 1, 2007 |
–22.3 |
–0.1 |
–4.2 |
– |
–0.4 |
–27.0 |
–0.4 |
|
Currency translation |
–0.2 |
– |
–0.3 |
– |
– |
–0.5 |
– |
|
Changes in companies consolidated |
– |
– |
– |
– |
– |
– |
– |
|
Depreciation and impairment losses |
– |
– |
– |
– |
– |
– |
– |
|
Disposals |
3.5 |
– |
– |
– |
– |
3.5 |
– |
|
Fair value adjustments of long-term investments taken directly to equity |
–1.3 |
– |
– |
– |
– |
–1.3 |
– |
|
December 31, 2007 |
–20.3 |
–0.1 |
–4.5 |
– |
–0.4 |
–25.3 |
–0.4 |
|
|
|
|
|
|
|
|
|
|
Net carrying amount |
74.4 |
27.3 |
1.1 |
11.7 |
15.8 |
130.3 |
1.4 |
As of December 31, 2007, non-current financial assets available for sale (investments) were carried at cost with a book value of €18.5 million since a market price could not be determined.
No non-current financial assets were reclassified between the individual categories of financial instruments during the fiscal year. The following amounts arising from non-current financial assets classified as “available-for-sale” were recognized in equity as of the balance sheet date:
| [ XLS ] |
|
€ million |
Available |
Available |
Total |
Available |
Available |
Total |
|
Fair values/ |
74.4 |
1.1 |
75.5 |
1,583.9 |
1.6 |
1,585.5 |
|
Amortized acquisition cost |
–73.5 |
–1.1 |
–74.6 |
–1,585.2 |
–1.6 |
–1,586.8 |
|
Unrealized gains/losses |
0.9 |
– |
0.9 |
–1.3 |
– |
–1.3 |
A statement of the Merck Group’s equity interests is filed with the electronic Federal Gazette and can be accessed at www.unternehmensregister.de . Major companies of the Merck Group as of December 31, 2007 are presented in the following table:
| [ XLS ] |
| |||||||||
|
Major companies of the Merck Group |
Direct equity |
Sales1 |
Profit |
Net equity1 |
Employees | ||||
|
|
|
|
|
|
| ||||
|
Germany/Europe |
|
|
|
|
| ||||
|
Merck KGaA, Darmstadt, Germany |
Parent company |
2,057.6 |
21.4 |
4,944.4 |
8,952 | ||||
|
Ares Trading S.A., Aubonne, Switzerland2 |
100.00 |
2,123.2 |
193.4 |
217.3 |
30 | ||||
|
Laboratoires Serono S.A., Coinsins, Switzerland2 |
100.00 |
1,336.7 |
–366.9 |
8,182.1 |
577 | ||||
|
Merck Serono S.p.A., Rome, Italy |
96.72 |
1,007.7 |
48.0 |
236.3 |
632 | ||||
|
Merck Lipha Santé S.A.S., Lyon, France |
100.00 |
435.3 |
23.9 |
60.2 |
498 | ||||
|
Merck Santé S.A.S., Lyon, France |
100.00 |
412.3 |
56.2 |
362.3 |
1,165 | ||||
|
Serono Benelux B.V., Den Haag, Netherlands |
100.00 |
382.1 |
2.1 |
6.9 |
44 | ||||
|
Merck Farma y Quimica S.L., Madrid, Spain |
100.00 |
366.8 |
15.1 |
90.8 |
947 | ||||
|
Merck Pharma GmbH, Darmstadt, Germany |
100.00 |
214.0 |
12.2 |
– |
380 | ||||
|
Serono GmbH, Darmstadt, Germany |
100.00 |
199.5 |
5.6 |
15.2 |
156 | ||||
|
Laboratoire Théramex S.A.M., Monaco |
99.88 |
102.9 |
6.6 |
35.0 |
384 | ||||
|
Merck CHC France Group, Lyon, France |
100.00 |
101.4 |
7.6 |
37.0 |
214 | ||||
|
Seven Seas Group, Hull, United Kingdom |
100.00 |
91.2 |
6.0 |
17.2 |
382 | ||||
|
Serono Ltd., Feltham, United Kingdom |
100.00 |
79.8 |
0.3 |
2.7 |
76 | ||||
|
Merck UK, West Drayton, United Kingdom |
100.00 |
76.7 |
12.4 |
15.2 |
222 | ||||
|
Serono France S.A.S., Lyon, France |
100.00 |
64.3 |
5.0 |
9.7 |
68 | ||||
|
Merck AG, Zug, Switzerland and Darmstadt, Germany |
100.00 |
– |
470.9 |
1,688.3 |
– | ||||
|
|
|
|
|
|
| ||||
|
North America |
|
|
|
|
| ||||
|
EMD Serono US Group, Rockland, MA United States |
100.00 |
635.0 |
54.5 |
214.7 |
671 | ||||
|
EMD Chemicals, Inc., Gibbstown, NJ United States |
100.00 |
246.3 |
14.5 |
235.9 |
960 | ||||
|
EMD Serono Canada Inc., Mississauga, Canada |
100.00 |
79.1 |
3.1 |
15.2 |
89 | ||||
|
|
|
|
|
|
| ||||
|
Latin America |
|
|
|
|
| ||||
|
Merck, S.A. de C.V., Mexico City, Mexico |
100.00 |
184.5 |
29.1 |
59.2 |
961 | ||||
|
Merck S.A., Rio de Janeiro, Brazil |
100.00 |
157.2 |
7.2 |
56.6 |
996 | ||||
|
Merck S.A., Caracas, Venezuela |
100.00 |
73.3 |
12.6 |
16.7 |
242 | ||||
|
Ares Trading Uruguay S.A., Montevideo, Uruguay |
100.00 |
67.7 |
21.6 |
11.7 |
15 | ||||
|
Serono Produtos Farmaceuticos Ltda., Sao Paulo, Brazil |
100.00 |
59.2 |
–5.3 |
1.7 |
69 | ||||
|
Merck S.A., Bogota, Colombia |
100.00 |
51.6 |
3.6 |
27.2 |
540 | ||||
|
|
|
|
|
|
| ||||
|
Asia, Africa, Australasia |
|
|
|
|
| ||||
|
Korean companies, South Korea |
100.00 |
399.8 |
52.4 |
95.6 |
325 | ||||
|
Taiwanese companies, Taiwan |
100.00 |
379.7 |
27.1 |
62.0 |
372 | ||||
|
Merck Ltd., Tokyo, Japan |
100.00 |
313.9 |
35.5 |
75.8 |
456 | ||||
|
Serono Singapore Pte. Ltd., Singapore |
100.00 |
62.9 |
–0.7 |
1.4 |
– | ||||
|
Merck Ltd., Mumbai, India |
51.00 |
55.6 |
10.8 |
76.7 |
922 | ||||
|
Merck Indonesia Group, Jakarta, Indonesia |
73.99 |
43.5 |
7.0 |
20.2 |
707 | ||||
